Gastric and oesophageal cancer trials in Italy

In Italy 71 Also abroad 1283

71 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 13 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
Where
Ancona, Aviano, Brescia, Candiolo, Caserta, Cremona, Florence, Milan, Modena, Naples, Parma, Perugia, Pisa, Ravenna, Reggio Emilia, Rome, San Giovanni Rotondo, Siena, Verona
Age
18 years and over
People
570 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07673887 · EU 2025-524557-14-00
Phase 1/2Taking people
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Where
Ancona, Candiolo (TO), Meldola (FC), Milan, Misterbianco (CT), Naples, Rozzano
Age
18 years and over
People
910 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT06324357
Phase 3Taking people
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Where
Ancona, Bergamo, Bologna, Brescia, Candiolo, Cremona, Florence, Meldola, Milan, Naples, Pisa, Reggio Emilia, Rome, Siena, Udine, Verona
Age
18 years and over
People
500 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT06901531 · EU 2024-519773-19-00
Phase 2/3Taking people
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Where
Milan, Naples, Padova, Rome, Turin
Age
18 years and over
People
690 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07221149 · EU 2025-523263-37-00
Phase 2Taking people
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Milan, Reggio Emilia, Rome
Age
18 years and over
People
111 worldwide
Run by
Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00
Phase 2Taking people
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
Where
Florence, Milan, Modena, Pisa, Rozzano, Udine, Vicenza
Age
18 years and over
People
100 worldwide
Run by
AstraZeneca
See details and how to joinNCT07069712 · EU 2024-516909-23-00
Phase 1/2Taking people
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Where
Milan
Age
18 years and over
People
560 worldwide
Run by
Genmab
See details and how to joinNCT03526835 · EU 2024-513627-16-01
Phase 1/2Taking people
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
Where
Rome
Age
18 years and over
People
160 worldwide
Run by
Eikon Therapeutics
See details and how to joinNCT07262619 · EU 2026-525248-13-00
Phase 1/2Taking people
BOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours
Where
Milan, Naples, Pisa
Age
18 years and over
People
220 worldwide
Run by
Bold Therapeutics, Inc.
See details and how to joinNCT04421820 · EU 2024-517500-11-00
Phase 1/2Taking people
A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
Where
Milan, Ravenna, Roma, Verona
Age
18 years and over
People
235 worldwide
Run by
Alentis Therapeutics AG
See details and how to joinNCT06747585 · EU 2024-515459-39-00
Phase 1/2Taking people
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
Where
Milan, Padova
Age
18 years and over
People
298 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06780111 · EU 2024-514273-22-00
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Bergamo, Genova, Naples, Verona
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Candiolo, Milan, Naples, Rome, Rozzano
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
Phase 3Taking people
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
Where
Ancona, Castellana Grotte, Genova, Milan, Naples, Padova, Pisa, Rome, Rozzano, Tricase
Age
18 years and over
People
510 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06644781 · EU 2023-509630-19-00
Phase 1Not yet taking people in Italy
A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
Where
Milan, Naples
Age
18 years and over
People
64 worldwide
Run by
Novartis Pharma AG
See details and how to join2024-518348-19-00
Phase 3Taking people
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Where
Florence, Milan, Monserrato, Naples, Padova, Rozzano, Tricase, Turin
Age
18 years and over
People
840 worldwide
Run by
AstraZeneca
See details and how to joinNCT06764875 · EU 2024-512583-57-00
Phase 3Taking people
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Where
Meldola, Milan, Padova, Rozzano, Tricase
Age
18 years and over
People
2,130 worldwide
Run by
AstraZeneca
See details and how to joinNCT07431281 · EU 2024-519787-40-00
Phase 3Taking people
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Where
Genoa, Milan, Pisa, Rozzano
Age
18 years and over
People
351 worldwide
Run by
BeOne Medicines
See details and how to joinNCT07043400 · EU 2025-522862-58-00
Phase 2/3Taking people
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
Where
Milan
Age
18 years and over
People
840 worldwide
Run by
Pfizer
See details and how to joinNCT07392892 · EU 2025-524717-86-00
Phase 1/2Taking people
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Where
Meldola, Milan, Naples, Roma, Rozzano
Age
18 years and over
People
1,438 worldwide
Run by
BioNTech SE
See details and how to joinNCT07070232 · EU 2024-517261-16-00
Phase 1/2Taking people
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Where
Meldola, Milan, Padova, Pisa
Age
18 years and over
People
230 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT05319730 · EU 2023-505189-26-00
Phase 1/2Taking people
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Where
Meldola, Milan, Pisa
Age
18 years and over
People
160 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06469944 · EU 2023-509307-33-00
Phase 2Taking people
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Where
Milan, Naples
Age
18 years to 130 years
People
454 worldwide
Run by
AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00
Phase 2Taking people
Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease
Where
Milan
Age
18 years and over
People
46
Run by
Gruppo Oncologico del Nord-Ovest
See details and how to joinNCT06253650
Phase 1/2Taking people
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Where
Ancona, Aviano, Meldola, Milan, Naples, Orbassano, Ravenna, Verona
Age
18 years and over
People
534 worldwide
Run by
Revolution Medicines, Inc.
See details and how to joinNCT06128551